Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.510
-0.330 (-17.93%)
At close: Feb 27, 2026, 4:00 PM EST
1.528
+0.018 (1.22%)
After-hours: Feb 27, 2026, 7:54 PM EST
Acrivon Therapeutics Employees
As of December 31, 2024, Acrivon Therapeutics had 78 total employees, including 75 full-time and 3 part-time employees. The number of employees increased by 17 or 27.87% compared to the previous year.
Employees
78
Change (1Y)
17
Growth (1Y)
27.87%
Revenue / Employee
n/a
Profits / Employee
-$1,048,090
Market Cap
47.65M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 78 | 17 | 27.87% |
| Dec 31, 2023 | 61 | 17 | 38.64% |
| Dec 31, 2022 | 44 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi Therapeutics | 124 |
| MindWalk Holdings | 102 |
| ImmuCell | 84 |
| Mereo BioPharma Group | 36 |
| Plus Therapeutics | 21 |
| NeurAxis | 21 |
| Lipocine | 16 |
| Instil Bio | 14 |
ACRV News
- 4 days ago - Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 5 days ago - Key Opinion Leader (KOL) Panel to Discuss Acrivon's ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress - GlobeNewsWire
- 10 days ago - Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory - GlobeNewsWire
- 5 weeks ago - Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress - GlobeNewsWire
- 7 weeks ago - Small-Cap Acrivon Highlights Tumor Shrinkage And Trial Progress Across Key Studies, Stock Falls - Benzinga
- 7 weeks ago - Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - GlobeNewsWire
- 7 weeks ago - Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast - GlobeNewsWire
- 2 months ago - UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast - GlobeNewsWire